These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prevalence of markers of hepatotropic viruses A, B, C and the efficacy of vaccination against hepatitis A and hepatitis B among medical students.
    Author: Jabłkowski M, Kuydowicz J, Strzelczyk J, Białkowska J.
    Journal: Med Sci Monit; 2002 Nov; 8(11):CR762-6. PubMed ID: 12444381.
    Abstract:
    BACKGROUND: Hepatitis A and B can be prevented by active immunization. The purpose of our study was to estimate the prevalence of viral markers of hepatitis A, B, and C among medical students, to assess the efficacy of vaccination against HBV infection after 4 years, and to evaluate the efficacy of vaccination against HAV infection. MATERIAL/METHODS: The study group consisted of 150 medical students, who were vaccinated with Engerix B at the beginning of medical studies. From this population we identified a subgroup of 45 students, in whom the presence of anti-HAV was not confirmed; they were then vaccinated with HAVRIX 1440. Viral markers for HAV, HBV, HCV were determined in this group. RESULTS: In the group of 150 persons, we found anti-HBc in 8 students (5.3%), and HBsAg in 1 (0.7%), who did not have either HBeAg or anti-HBe. Anti-HBs antibodies were found in 146 students (97.3%); anti-HCV in 3 cases (2%), and anti-HAV in 15 cases (10%). After 2-fold vaccination against viral hepatitis A, 100% of the students presented with anti-HAV. CONCLUSIONS: The incidence of HBsAg and anti-HCV among our students is the same as in the general population, while the incidence of anti-HAV is much lower (10%). The presence of anti-HBs 4 years after vaccination was detected in 97.3% of the students, and anti-HAV 1 month after the complete course of vaccination in 100% of cases.
    [Abstract] [Full Text] [Related] [New Search]